Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tioma Therapeutics Inc.

www.tiomatherapeutics.com

Latest From Tioma Therapeutics Inc.

Finance Watch: Arteaus Comes Full Circle As Investors Monetize Emgality Royalties

Arteaus sells royalty stream from Lilly's Emgality giving investors a $260m payday. Also, Pfizer spin-out SpringWorks nabs another $125m, Arch Oncology and Prevail Therapeutics close $50m Series B rounds, and Karuna's recent financing grows to $80m.

Financing StartUps and SMEs

Forty Seven's IO Antibody Attracts Two Big Pharma Partners

Forty Seven Inc. has signed immuno-oncology deals with Merck of Germany and Roche that will see the launch of several combination studies for their PD-L1 inhibitors and Forty Seven's promising investigational CD47 antibody.

ImmunoOncology Deals

Early Stage Biopharma Financings Kept Up Multibillion-Dollar Pace In 2016

Series A venture capital and seed funding rounds for biopharma firms in 2016 kept pace with the level of investment seen in 2015, excluding one major deal in 2015, laying the foundation for optimism regarding early-stage financings in 2017 for particularly innovative companies.

Financing StartUps and SMEs

Trillium Looks To Lead The Immuno-Oncology Pack In CD47 Inhibition

Emerging Company Profile: Toronto biotech thinks it will differentiate from the current IO paradigm with CD47 inhibition, and from competitors in its space by directly targeting a receptor found in the tumor microenvironment.

StartUps and SMEs Cancer
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Vasulox
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Tioma Therapeutics Inc.
  • Senior Management
  • John Donovan, Pres. & CEO
    Robert W Karr, MD, CSO
    James Stutz, CBO
  • Contact Info
  • Tioma Therapeutics Inc.
    Phone: (314) 932-4032
    4320 Forest Park Ave.
    Ste. 304
    St. Louis, MO 63108
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register